<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">METYROSINE</span><br/>(me-tye'roe-seen)<br/><span class="topboxtradename">Demser<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">enzyme inhibitor</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Blocks the enzyme tyrosine hydroxylase to inhibit the conversion of tyrosine to DOPA, which is the initial and rate-setting
         step in synthesis of catecholamines (dopamine, epinephrine, norepinephrine).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>In patients with pheochromocytoma, reduces catecholamine synthesis as much as 80%, ameliorating hypertensive attacks and
         associated symptoms.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term management of pheochromocytoma until surgery is performed, in long-term control when surgery is contraindicated,
         and in patients with malignant pheochromocytoma.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Has been used in selected patients with schizophrenia to potentiate antipsychotic effects of phenothiazines.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Control of essential hypertension. Safety during pregnancy (category C), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired liver or kidney function.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Pheochromocytoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg q.i.d., may increase to 23 g/d in divided doses (max: 4 g/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give each dose with a full glass of water and be consistent about time medication is to be taken.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Sedation,</span> fatigue; <span class="speceff-common">extrapyramidal signs: drooling, difficulty in speaking (dysarthria), tremors,</span> jaw stiffness (trismus); frank parkinsonism, psychic disturbances (anxiety, depression, hallucinations, disorientation, confusion),
      headache, muscle spasms. <span class="typehead">GI:</span> <span class="speceff-common">Diarrhea,</span> nausea, vomiting, abdominal pain, dry mouth. <span class="typehead">Skin:</span> Rash, urticaria. <span class="typehead">Urogenital:</span> Transient dysuria, crystalluria, hematuria, impotence, failure of ejaculation. <span class="typehead">Endocrine:</span> Breast swelling, galactorrhea. <span class="typehead">Body as a Whole:</span> Peripheral edema, nasal stuffiness, shortness of breath. <span class="typehead">Hematologic:</span> Eosinophilia. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>False increases in <span class="alt">urinary catecholamines</span> may occur because of catechol metabolites of metyrosine.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol</b> and other <span class="classification">cns depressants</span> add to sedation and CNS depression; <b>droperidol,</b> <b>haloperidol,</b> <span class="classification">phenothiazines</span> potentiate extrapyramidal effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 23 d. <span class="typehead">Duration:</span> 34 d. <span class="typehead">Distribution:</span> Crosses bloodbrain barrier. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 3.47.2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effectiveness with frequent assessment of vital signs.</li>
<li>Monitor I&amp;O ratio and pattern. Fluid intake must be enough (e.g., 1012 glasses or more) to maintain urinary output of
            2000 mL or more to minimize risk of crystalluria.
         </li>
<li>Perform routine urinalysis; if crystals occur, increase fluid intake further. If crystalluria persists, decrease drug dosage
            or discontinued.
         </li>
<li>Lab tests: Obtain baseline and periodic measurements of urinary catecholamines and their metabolites (metanephrines and VMA).
            Metabolite excretion should decrease in patients with pheochromocytoma. Other baseline and regular determinations include
            kidney and liver function tests (in patients with dysfunction), and blood and urine glucose tests.
         </li>
<li>Supervise ambulation. Sedative effects occur commonly within the first 24 h after drug is started. Maximal sedative effects
            in 2 or 3 d.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician if following adverse effects occur: Diarrhea, particularly if it is severe or persists, painful urination,
            jaw stiffness, drooling, difficult speech, tremors, disorientation. Dosage reduction or discontinuation of drug may be indicated.
         </li>
<li>Avoid driving and potentially hazardous activities until response to drug is known.</li>
<li>Be aware that abrupt withdrawal of metyrosine may result in psychic stimulation, feeling of increased energy, temporary changes
            in sleep pattern (usually insomnia). Symptoms may last for 2 or 3 d.
         </li>
<li>Carry medical identification at all times if on prolonged therapy and notify all physicians and dentists involved in care
            about drug regimen.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>